On February 16, 2021 GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on the development and commercialization of its disruptive, target-directed Natural Killer (NK) cell engager immunotherapy protein biologic platform technology: TriKE for cancer and infectious diseases, reported the closing of an underwritten public offering of 4,300,000 Units (Press release, GT Biopharma, FEB 16, 2021, View Source [SID1234575091]). Each Unit consisted of one share of GT Biopharma’s common stock and one warrant to purchase one share of common stock at a public offering price of $5.50 per share, per Unit. In addition, the Company has granted the underwriters a 45-day over-allotment option to purchase up to an additional 645,000 Units, less underwriting discounts and commissions.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Gross proceeds from the offering are approximately $23.6M, before deducting underwriting discounts and commissions and offering expenses, but excluding any exercise of the underwriters’ over-allotment option. Following the offering, the Company’s cash position is approximately $30M, extending GT Biopharma’s cash runway through 2022. The transaction successfully extinguished over $25M in debt, which converted into equity, without the need to exercise a downward reset and consolidated the Company’s capital structure to 20,637,000 shares issued and outstanding.
Anthony J. Cataldo, GT Biopharma’s Chairman and CEO, commented: "Completing our financing and uplisting to NASDAQ was a major milestone for us and a significant move to increase GT’s corporate reach. We have long been recognized to have a disruptive platform NK technology, TriKE, as demonstrated with the ongoing results of our FDA-approved expanded GTB-3550 TriKE Phase 1/2 clinical trial. This was evidenced by the very positive response to our oral data presentation at the ASH (Free ASH Whitepaper) (American Society of Hematology) conference in December. Now, as a repositioned biotech NASDAQ trading company, institutional funds and analysts are no longer restricted from participating with GT Biopharma, Inc. With this infusion of capital set to advance both liquid and solid cancer TriKEs in the clinic, and partnership opportunities on the horizon for targeted TriKE licensing programs, this is a most auspicious time for the Company. We are very excited to have our corporate structure on par with the quality of human data, which thus far has shown no signs of toxicity or side effects; but has shown clinical benefit in our GTB-3550 TriKE Phase 1/2 expansion trial for Acute Myeloid Leukemia (AML) and Myelodysplastic syndromes (MDS). This is the first of our several planned cancer trials later this year."
Roth Capital Partners and Dawson James Securities, Inc. acted as joint book-running managers for the offering.